Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug 21;20(7-8):538–548. doi: 10.1080/21678421.2019.1646769

Table 2.

Serum and CSF pNfH concentration

Baseline Visit Only All Available Visits (Baseline & Follow Up)
Control At-risk Converter b Affected Control At-risk Converter c Affected
Serum pNfH: Samples available:
pNfH below LOD a:
N=34
N=2
N=79
N=6
N=14
N=0
N=22
N=0
59 visits
3 visits
224 visits
17 visits
42 visits
2 visits
68 visits
0 visit
 Original scale (pg/ml) Median
(Range)
22.9
(0.03-113.2)
20.6
(1.2-212.7)
12.7
(0.6-366.6)
84.7
(2.0-1,156)
25.7
(0.03-124.9)
22.1
(0.03-212.7)
43.4
(0.6-1,156)
75.1
(1.1-1,156)
 Log-transformed d Mean ± SD
(Range)
2.9 ± 1.3
(0-4.7)
3.0 ± 1.0
(0.8-5.4)
2.8 ± 1.5
(0.4-5.9)
4.2 ± 1.7
(1.1-7.1)
3.1 ± 1.2
(0-4.8)
2.9 ± 1.0
(0-5.4)
3.9 ± 1.6
(0.4-7.1)
4.2 ± 1.5
(0.7-7.1)
CSF pNfH: Samples available e: N=15 N=46 N=7 N=9 21 visits 116 visits 20 visits 23 visits
 Original scale (pg/ml) Median
(Range)
253
(24-1,321)
252
(109-612)
852
(109-3,900)
1,657
(639-11,418)
253
(24-1,321)
278
(73.7-1,137)
2,853
(109-12,244)
1,782
(639-11,418)
 Log-transformed d Mean ± SD
(Range)
5.5 ± 0.9
(3.2-7.2)
5.5 ± 0.4
(4.7-6.4)
6.5 ± 1.2
(4.7-8.3)
7.6 ± 0.9
(6.5-9.3)
5.5 ± 0.8
(3.2-7.2)
5.6 ± 0.5
(4.3-7.0)
7.7 ± 1.3
(4.7-9.4)
7.6 ± 0.8
(6.5-9.3)

Baseline = first visit at which serum sample was available (with or without contemporaneous CSF collection)

N = number of participants. Visits = number of person-visits. LOD = limit of detection.

a

These observations were assigned the lowest detectable value in analyses and figures, but excluded from the calculation of summary statistics presented in this table.

b

All 14 converters were pre-symptomatic at baseline.

c

The 42 person-visits in the converter group included visits from when participants were pre-symptomatic and after phenoconversion.

d

Natural algorithm

e

None of the pNfH concentrations was below the limit of detection. N=11 participants (N=1 control, N=7 at-risk, N=3 converters) had CSF pNfH only at follow-up visits. Their data are included in the “All Available Visits” columns but not the “Baseline Visit Only” columns.